Dipeptidyl peptidase-4 (DPP-4) inhibitors, employed primarily to manage type 2 diabetes, function by inhibiting the degradation of glucagon-like peptide-1 (GLP-1), thus facilitating glycemic control. The gene discussed is GCG; the disease is type 2 diabetes mellitus.